CWF Editing for Autologous Cellular Immunotherapy Treatment of Metastatic Prostate Cancer (PROVENGE®)
This CR will provide for edits, implemented on July 2, 2012, for CWF to reject and contractors to deny claims for PROVENGE therapy where more than 3 claims had been paid in a patient’s lifetime.
Final
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: January 25, 2012
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.